Avacta Group (LON:AVCT) Trading Up 7.5% - Should You Buy?

Key Points

• Avacta Group's stock price surged 7.5% during trading on Friday, reaching a last price of GBX 59.12 ($0.80) after trading as high as GBX 60 ($0.81).
• The company reported a negative return on equity of 74.00% and a negative net margin of 114.45%, with equity analysts forecasting EPS of -9.9011833 for the current fiscal year.
• Avacta Group operates as a clinical stage biopharmaceutical company focused on enhancing drug delivery methods through its proprietary pre|CISION® platform.

Avacta Group Plc (LON:AVCT - Get Free Report)'s share price rose 7.5% during trading on Friday . The stock traded as high as GBX 60 ($0.81) and last traded at GBX 59.12 ($0.80). Approximately 6,621,586 shares changed hands during mid-day trading, an increase of 218% from the average daily volume of 2,079,640 shares. The stock had previously closed at GBX 55 ($0.74).

Avacta Group Stock Performance

The business has a 50 day moving average of GBX 41.37 and a 200 day moving average of GBX 37.82. The company has a market capitalization of £247.09 million, a P/E ratio of -400.91 and a beta of 1.12. The company has a quick ratio of 4.96, a current ratio of 1.29 and a debt-to-equity ratio of 52.53.

Avacta Group (LON:AVCT - Get Free Report) last announced its quarterly earnings results on Friday, June 6th. The biotechnology company reported GBX (8.54) EPS for the quarter. Avacta Group had a negative net margin of 114.45% and a negative return on equity of 74.00%. On average, sell-side analysts predict that Avacta Group Plc will post -9.9011833 earnings per share for the current year.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).